Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Inclacumab by Pfizer for Sickle Cell Disease With Vaso-Occlusive Crisis: Likelihood of Approval
Inclacumab is under clinical development by Pfizer and currently in Phase III for Sickle Cell Disease With Vaso-Occlusive Crisis. According...
Data Insights
Risk adjusted net present value: What is the current valuation of Pfizer's Inclacumab?
Inclacumab is a monoclonal antibody commercialized by Pfizer, with a leading Phase III program in Sickle Cell Disease With Vaso-Occlusive...